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Background. The functional diffusionmap (fDM) has been suggested as a tool for early detection of tumor treatment efficacy.We aim to
study 3 factors that could act as potential confounders in the fDM: areas of necrosis, tumor grade, and change in tumor size.
Methods. Thirty-four pediatric patientswith brain tumorswere enrolled in a retrospective study, approved by the local ethics committee,
to examine the fDM. Tumorswere selected to encompass a range of types and grades. A qualitative analysis was carried out to compare
how fDM findings may be affected by each of the 3 confounders by comparing fDM findings to clinical image reports.
Results.Results show that the fDM in areas of necrosis donot discriminate between treatment responseand tumor progression. Further-
more, tumorgradealters thebehaviorof the fDM: adecrease in apparentdiffusion coefficient (ADC) is a signof tumor progression inhigh-
grade tumors and treatment response in low-grade tumors. Our results also suggest using only tumor area overlap between the 2 time
points analyzed for the fDM in tumors of varying size.
Conclusions. Interpretation of fDM results needs to take into account the underlying biology of both tumor and healthy tissue. Careful
interpretation of the results is required with due consideration to areas of necrosis, tumor grade, and change in tumor size.
Keywords: apparent diffusion coefficient, functional diffusion map, parametric response map, childhood tumors, diffusion-weighted
magnetic resonance imaging.
Brain tumors are the most common solid tumor in children and
differ inbiologyanddevelopment fromadultbrain tumors. Fewbio-
logical markers have been studied in childhood brain tumors com-
pared with adults due to the relative rarity of the tumors. Limited
literature studying childhood brain tumors, as compared to those
in adults, thus exists; and these studies tend to include low
patient numbers who receive diverse treatment regimens.1,2
Diffusion-weighted imaging (DWI)hasbeenutilizedasa tool for
tumor diagnosis3 and prognosis4 in childhood brain tumors. By
measuring the diffusion ofwatermolecules in tissue and quantify-
ing this in terms of the apparent diffusion coefficient (ADC), DWI is
able to image cellularity as a consequence of water diffusion re-
striction in more densely packed tumors.5 The functional diffusion
map (fDM), also knownas theparametric responsemap, compares
ADCchangesover time. In the fDM,avoxel-wisecomparisonofpre-
andposttreatmentADCmaps is carriedout in the tumorareas, and
the difference in ADC is labeled in blue, green or red depending on
whether a decrease, no change or an increase in ADC, respectively,
was observed. In published studies, an increase in ADC is said to
reflect a decrease in tumor cellularity and a good treatment re-
sponse, whereas a decrease in ADC is said to reflect an increase
in tumor cellularity and a poor treatment response. The fDM has
thus been proposed as a tool tomonitor early treatment response
andefficacy inanattempt to identify patientswhowill benefit from
further adjuvant therapy prior to a change in tumor size, which is
the more conventional measure of tumor response.6–8
Our studyexamines3 factors identifiedaspossible confounders
for the fDM in childhood brain tumors; and we hypothesize that
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necrosis, tumor grade, and change in tumor size need to be taken
into consideration when interpreting fDM analysis in childhood
brain tumors.
Firstly, tumor necrosis can be seen followingboth tumorgrowth
(eg, as the tumor outgrows its blood supply) as well as a result of
successful treatment. Limited literature exists linking areas of ne-
crosis to survival; one study in patients with osteosarcoma
showed no correlation between 90% necrosis and survival and
suggested that more data were required to determine a possible
correlation between 70% necrosis and survival.9 In another,
earlier study in childrenwithbrain stemgliomas treatedwith radio-
therapy, no association was found between the absence or pres-
ence of necrosis postradiation and outcome.10 Furthermore, the
presenceorabsenceofnecrosisasaprognostic factor isdependent
on the disease type in which it occurs. It is also being debated
whether the inflammation in necrotic areas carries a goodprogno-
sis or not,11 as it is possible that a certain degree of necrosis may
induce angiogenesis through the immune inflammatory cells
that necrotic cell death promotes.12 We therefore aimed to study
whether the fDM in necrotic areas discriminated between treat-
ment outcome.
Secondly, tumor cellularity varies by tumor type and grade, and
weapplied the fDMtechnique to tumorsof varyinggrades toestab-
lish its utility throughout a range of childhood tumors. Thirdly,
some tumors change considerably in size after treatment. Since
this may cause problems of registration, we aimed to identify
whether the fDM can be successfully applied in these cases.
Materials and Methods
Patients
Thirty-four childhood brain-tumor patients (19 male, 15 female; aged
4months to 16.5 years;mean7.8 years), who hadDWI as part of their clin-
ical imaging between 2005 and 2012, were enrolled in a retrospective
study. Ethical approval was given by the local ethics committee.
Informedconsentwasnot required for imagingdataas thiswasobtained
for clinical purposes. Informedconsentwas obtained in those caseswere
histology was used. All data were anonymized in accordance with the
Data Protection Act.
Cases were selected so that fDM characteristics could be evaluated
across a rangeof tumor types andgrade. Caseswere retained that had clin-
ical DWI data available at 2 time points, with no surgery taking place
between the 2 time points (whichwould obviate ameaningful assessment
of the fDM) andwith a significant tumor volume present in both images. Of
the 34 patients, 18 were diagnosed with diffuse intrinsic pontine glioma
(DIPG), 6 with optic pathway glioma (OPG), 4 with tuberous sclerosis and
subependymal giant cell astrocytoma (SEGA), 3 with glioblastoma multi-
forme (GBM), and 3 with gliomatosis cerebri (GC). Histological diagnosis
was confirmed in 4 SEGA patients, 3 GBM patients, 2 GC patients, and 1
OPG patient. In the remainder, the diagnosis wasmade on neuroradiologi-
cal groundswith imaging discussed in amultidisciplinary team setting and
acceptedas abasis for treatment. Thediagnostic histologywas reviewed in
2 patients (1 GBM and 1 OPG) and compared with that from a patient
showing normal-appearing white matter.
Image Acquisition
Imaging datawere acquired on a 1.5T Siemens Magnetom Symphony MRI
scanner, with a maximummagnetic field gradient strength of 30 mTm21,
and on a 1.5T Siemens Avanto scanner, with a maximum magnetic field
gradient strength of 40 mTm21. DWI datawere obtained using a diffusion-
sensitized single-shot echo planar imaging sequence (b¼ 0, 500, 1000 s
mm22). The clinical ADC, using all 3 b-values, was used in this analysis. Dif-
fusion gradients were applied in 3 orthogonal directions, with an image
matrix of 128 by 128 and field of view of 230 by 230 mm. On the Avanto
scanner, 19 slices were acquired with a 5 mm thickness, 1.5 mm gap, and
a total sequence time of 64 seconds, with TR¼ 2700 ms and TE¼ 96 ms.
The Symphony protocol specifies 20 slices with a 5 mm thickness, 2.5 mm
gap, and a total sequence time of 56 seconds, with TR¼ 3600 ms and TE¼
107 ms.
fDM Analysis
Fig. 1 showshowthe fDM is constructed. Prior tobuilding the fDM,ADCmaps
at the time points analyzedwere coregistered to the patient’s T2-weighted
image at diagnosis or postsurgery to exclude major changes in the tumor
due to surgery. Where pretreatment images were not available, as some
patients would have arrived at our institution with these images already
having been taken, 2 posttreatment images were used. MATLAB (Math-
Works) and SPM8 (Wellcome Trust Centre for Neuroimaging) were used
for coregistration, applying the standard normalized mutual information
and a trilinear interpolation algorithm. A visual inspection was carried out
on all coregistered images to ensure successful registration.
The fDM, implemented in MATLAB, was applied in tumor areas by speci-
fying a region of interest (ROI) using FSLView (FMRIB). ROIs were defined
across all tumor image slices by considering both ADC and T2-weighted
images, including tumor regions andareas of necrosis but excluding peritu-
moral edema where possible. The tumor boundary was identified using
both ADC and T2 weighted images. Areas of bright ADC outside the
defined tumor boundary were considered to be peritumoral edema and
were excluded. Infiltrative edema was included in the analysis as it
Fig. 1. Construction of the fDM. The fDM is built byusing tumor images at 2 timepoints. After registration of the 2 images, a difference image is calculated.
A decrease in ADC is labeled in blue, an increase in ADC is labeled in red, and no change in ADC is labeled in green.
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cannot be easily differentiated from tumor using ADC and T2 weighted
imaging.
Avoxel-wisecomparisonwascarriedout,over thewhole tumor,on the2
time points being investigated. Specific thresholds were used to determine
whether there was an increase, decrease, or no change in ADCwhen com-
paring ADC images. This study employed the suggested threshold of 0.40×
1023 mm2 s21, the threshold indicating the highest sensitivity and specifi-
city in the receiver operating characteristic (ROC) analysis.8 Thismeans that
a voxel with ADC increasing by more than this value was classified as in-
creasing in ADCanddisplayed in red in the fDM. AvoxelwithADCdecreasing
by more than this threshold was classified as decreasing in ADC and dis-
played in blue. Any voxels with an ADC change between these thresholds
were classified as not changing in ADC and were displayed in green. fDM
findings were compared with clinical imaging reports in order to identify
whether the fDM correctly identified tumor response from tumor progres-
sion as reported by the clinical radiologist.
Areas of Necrosis
By showing the biological processes involved in the fDM,Moffat et al. briefly
mentioned that necrotic or cystic regions can undergo a displacement of
water resulting in a reduction in ADC as tumor cells move into the area.6
In addition to this, in theory, areas of necrosis can increase or decrease in
size irrespective of treatment outcome. Fig. 2 shows a flow map for the
different possible outcomes of treatment response in terms of necrotic
areas within the tumor.
The fDM was studied in areas of necrosis in patients with DIPG and
with GC, as these were the cases that showed the most necrosis as
compared with the other groups studied. Areas of necrosis were identi-
fied in each image as those voxels with an ADC value higher than 1.8×
103 mm2 s21 –, a value observed to make up most of the necrotic
regions while excluding both normal and tumor tissue. The ROI was
selected such that only tumor areas visible on both pre- and posttreat-
ment images were included in the analysis. A comparison was made
between fDM tumor treatment response classification when including
and excluding necrosis to test the hypothesis that necrotic areas act
as a confounder in the fDM.
Tumor Grade
Most fDMstudieshave beencarried out on adults in high-grade tumors.13–15
Given that high- and low-grade tumors differ in ADC3, the corresponding
fDM may also differ in terms of treatment response classification. Fig. 3
shows the theoretical changes that can occur to the ADC and the fDM
when high- and low-grade tumors respond to treatment or show signs of
progressivedisease. The fDM inhigh-grade (GBM,WHOgradeIV),mid-grade
(DIPG, WHO grades II and III), and low-grade (OPG, WHO grade I) tumors
were analyzed, and findings were compared with the outcome described
Fig.2. Theoretical change inareasofnecrosisbytreatment.Necroticareasofatumorcan increase insizeasa resultof (A) tumorgrowth (causing increased
hypoxic regions and hence necrosis) and (B) successful treatment (as cells are killed, tumor regions are replaced by areas of necrosis). Conversely, a
reduction in size of necrotic regions can be due to (C) tumor growth through angiogenesis (making the tumor more vascular and hence more cellular in
areas that would otherwise have been necrotic), and (D) tumor size reduction due to successful treatment (as the tumor shrinks in size, areas of
necrosis may be replaced by glial cells).
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in clinical reports obtained at the time of the follow-up (second) imaging
session.
Change in Tumor Size
SEGApatientswere found to respondwell to rapamycin,16 and the effect of
a reduction in tumor sizewasaddressedbyanalyzing the fDM in this patient
group as therewas a good response to treatment, with the tumor decreas-
ing in size considerably in 3 of 4 cases. The imageswere analyzed using first
a pretreatment mask and then the overlap between the pretreatment
tumorareasandposttreatment tumorareas. fDMfindingswereagaincom-
pared with clinical imaging reports at the time of the follow-up (second)
image.
Statistical Analysis
In order to analyze the fDM in areas of necrosis and in tumors of varying
grade, contingency tables were constructed (Tables 1 and 2). Fisher’
exact test17 was applied to these tables using MATLAB and a predefined
function.18 Contingency tables show how categorical variables are
related to each other by representing the frequency distribution of the vari-
ablesanalyzed. Fisher’ exact testallows for theanalysesof such tables, par-
ticularly when the sample size is small.
Results
Of the patients included in this study, none of the DIPG and OPG
patients had partial or total resection of tumor. Two GBM patients,
1GCpatient,andall 4SEGApatientshadpartial or total resectionof
tumor. The fDMwas built in 11 patients pre- and post treatment, in
20patientsusing2posttreatment images,and in3patientsusing2
pretreatment imageswhere a “watch andwait” or a palliative care
protocol was employed. The time interval between the 2 images
ranged from 2 weeks to 13 months.
Areas of Necrosis
In theDIPGpatient group, the tumorareaconsisted, on average, of
11.2% necrosis, while the GC patient group had on average 31.6%
necrosismeasured by calculating the percentage of voxels with an
ADC higher than 1.8×1023 mm2 s21 in the tumor ROI. Ten of 18
patients with DIPG and all 3 patients with GC showed areas of ne-
crosis.5%. In all of these cases, an increase or decrease in ADC in
areas of necrosis was related to an increase or decrease in size of
necrotic regions, respectively,andwasnot related to the treatment
response identified in clinical image reports. Table 1 shows a
summary of the fDM in necrotic areas and how these related to
the size of necrotic areas and clinical response. Fisher’ exact test
on this data confirmed the fDM in areas of necrosis to be related
to the change in size of necrotic areas (P, .001) and not related
Fig. 3. Theoretical changes in the fDM in tumorsof varyinggrade. (Red representsan increase,blueadecrease, andgreennochange inADC). Theupperhalf
of the image shows the theoretical change in ADC in high-grade tumors, which appear dark with low ADC values. (A) Progressive high-grade tumors will
increase in cellularityand result ina loweranddarkerADCvalue (blue in fDM). (B) Conversely, ahigh-grade tumor respondingwell to therapywill decrease in
cellularityand increase inADCtovaluesmoresimilar to thoseofhealthy tissue (red in fDM). The lowerhalf of the imageshowsthe theoretical change inADC
in low-grade tumors,whichappearbrightwithhighADCvalues. (C) Inprogressivedisease, it is expected that the tumorwill eithergroworbecomenecrotic.
Hence, excluding areas of necrosis, it is not expected to change in ADC (green in fDM), which is also indicative of stable disease. (D) Low-grade tumors that
respond to therapy are likely to be replaced by lower ADC healthy tissue, and hence, responsive low-grade tumors would decrease in ADC (blue in fDM).
Table 1. The fDM in necrotic areas compared with clinical response and
change in size in necrotic areas
fDM in Necrotic Areas: Inc NC Dec P value
Size of necrotic area Increase 6
No change 3
Decrease 4 P, .001
Clinical response Response 3 1 1
Stable 2
Progression 1 2 3 P¼ .31
Abbreviations: Dec, decrease in apparent diffusion coefficient; fDM,
functional diffusion map; Inc, increase in apparent diffusion coefficient;
NC, no change.
Table 2. fDM changes by tumor grade and clinical response
Tumor Grade: High Mid Low P value
fDM increase
in ADC
Clinical
Response
Response 1
Stable
Progression 5 1 P, .001
fDM no change Clinical
Response
Response 2
Stable 3 6
Progression 1 3 P¼ .04
fDM decrease
in ADC
Clinical
Response
Response 5 4
Stable
Progression 2 P, .001
Abbreviations: ADC, apparentdiffusion coefficient; fDM, functional diffusion
map.
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to clinical response (P¼ .31). When classifying tumor response
using the fDM, excluding areas of necrosis made a difference in 4
of 21 cases studied. Fig. 4 shows 2 examples of the fDM showing
an increase in ADC in areas of necrosis, while clinical image
reports identified stable disease in both cases.
Tumor Grade
The fDM in GBM (high-grade) showed areas of decreased ADC at
progression andareas of increasedADCwith positive treatment re-
sponse. Conversely, in DIPG (mid-grade) and OPG (low-grade), the
fDM showed areas of increased ADC at progression and areas of
decreased ADC at tumor treatment response (Fig. 5). In the lower-
grade tumors, it was noted that an increase in ADC was mostly
associated with an increase in necrotic/cystic components of the
tumor.
Table 2 shows a summary of the changes in the fDM according
to tumor grade and response. Fisher’ exact test showed that there
was a significant difference between tumor grade and clinical re-
sponse for the increase and decrease in ADC (P, .001). The com-
parison between grade and clinical response when the tumor
fDM did not change was only marginally significant (P¼ .04).
Of the3GBMpatients, oneshowedsmall areasof increasedADC
at response and large areas of decreased ADC at progression.
A secondpatient showed small areas of decreasedADCatprogres-
sion. In the third patient, negligible changes in ADCwere observed
at progression.
Of the 18 DIPG patients, 8 progressed at second imagingwith 5
showing an increase in ADC and 3 showingminor to no changes in
ADC; 7 responded to treatment, with 5 showing a decrease in ADC
and 2 showing minor to no changes in ADC; 3 showed stable
disease with minor changes in ADC.
Of the 6 OPG patients, 4 showed areas of decreased ADC at
treatment response and minor to no change at stable disease,
with one of these patients progressing at a later time point and
showing increased ADC; 2 patients showed minor to no changes
in ADCwith stable disease.
Change in Tumor Size
Of the 4 SEGA patients analyzed, there was a large decrease in
tumor size in 3 patients. When using pretreatment masks, the
fDM showed a large area of decreased ADC in the 3 SEGA patients
responding to treatment. These areaswere excluded from the fDM
when looking at only the overlap (Fig. 6). Outside of the tumor
overlap areas, a decrease in ADC was observed when tumor
areas were replaced by healthy tissue, and an increase in ADC
wasobservedwhentumorareaswere replacedbyareasof cerebro-
spinal fluid. In selecting only tumor overlap areas, amore accurate
assessment of the fDM findings was therefore given, although
results did not indicate that the fDM gave any more information
than standard clinical imaging reports.
Histology
A comparison of high-grade (GBM), low-grade (OPG), and normal-
appearingwhitematter is showninFig.7. The low-gradetumorhad
some areas of increased cellularity compared with normal-
appearing white matter and some myxoid areas with a loose
microcystic stroma. This may help explain the increased ADC
observed in low-grade tumors. The high-grade tumor showed
the highest cellularity; due to this restricted diffusion, these
tumors appear dark in an ADC image.
Discussion
Determining treatment response early on in the treatment cycle is
of vital importance for moving toward personalizedmedicinewith
the ability to alter doses or change therapy in those cases where
the current treatment is seen to be ineffective. The fDMwas previ-
ously shown to be an effective biomarker for detecting treatment
response earlier than current standard techniques that consist of
radiological assessment, in most cases at the end of therapy.13
However, in this analysis, a number of limitations have been iden-
tified and studied, which indicates the need to exercise caution
when interpreting fDM results.
Areas of Necrosis
Necroticareasofatumorcan increase insizebothasa resultof suc-
cessful treatment (as cells are killed, tumor regions are replacedby
areas of necrosis) and as a result of tumor growth (causing
Fig. 4. The fDM in areas of necrosis. The DIPG patient was treated with
radiotherapy and chemotherapy, and the fDM was constructed from 1
post treatment image and a 3-month follow-up image. (A and B) The fDM
in DIPG shows areas of increased ADC (red) (A) that are eliminated when
excluding areas of necrosis (B). The GC patient was treated via surgery
followed by chemotherapy, and the fDM was constructed from 1 image
taken 3 months after start of chemotherapy and a 1-year follow-up
image. (C and D) The fDM in GC showed areas of increased ADC in necrotic
regions (C) , which were again eliminated when necrotic regions were
excluded (D). Removal of the necrotic regions is concordant with no
tumor response in 2 patients with no change in tumor size.
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increased hypoxic regions and hence necrosis). Our results have
shown the fDM does not give an accurate interpretation of treat-
ment response in areas of necrosis. An increase/decrease in ADC
in these areas was mostly related to an increase/decrease in nec-
rotic areas rather than positive treatment response or progression.
Eliminating areas of necrosis made a difference in treatment re-
sponse classification in 20% of the cases studied. Given that such
areas may act as a potential confounder in the fDM, we suggest
excluding them from the fDM in order to accurately assess tumor
response.
Tumor Grade
Our results have identified tumor grade as a potential confounder
in the fDM, and we have shown the importance of taking this into
consideration in analyzing the fDM. Previous publications have
shown an increase in ADC in the fDM to be indicative of positive
treatment response6 and a decrease in ADC to be indicative of
tumor progression.15 This concept is underpinned by research
that showed the ADC to be inversely correlated with cellularity.5
This was based on the assumption that the ADC is lower in tumor
tissue than in surrounding healthy tissue due to the increased cel-
lularity of tumors. While this is valid in high-grade tumors, tumor
tissue can include microcystic areas or areas of infiltrative edema
in lower-grade tumors, which drives the ADC up even though the
cellularity of the tumor itself may be higher than that of surround-
ing tissue.3 Unless there is tumor progression from low- to high-
grade, a decrease in ADC in low-grade tumors is therefore likely
to be a sign of treatment response as the higher ADC tumor
Fig. 5. The fDM in tumorsof varyinggrade.Acomparison is shownof the fDM inGBM (AandD), DIPG (BandE), andOPG (CandF) in areasofprogression (top
row) and treatment response (bottom row). (A) In high-grade tumors, a decrease in ADC (blue)was indicative of an increase in cellularity and progression.
(EandF) Inmid-and low-grade tumors, adecrease inADCwas indicative of positive treatment responseashighADCtumorwas replacedbyhealthy tissue.
(D) Similarly, an increase in ADC (red) was indicative of positive treatment response in high-grade tumors, and in the above cases (B and C), progression in
mid- and low-grade tumors (B and C). Tumor progression and treatment response were defined by a radiologist at the time of second imaging.
Fig. 6. Change in tumor size. (A andC) A comparison of the fDMwhenusing
a pretreatment mask and (B and D) only the overlap between pre- and
posttreatment images is shown in a SEGA patient. The top row shows
T1-weighted postcontrast imaging. The bottom row shows the fDM in 1
case, showing (C) a mixture of areas of increased ADC (red) and
decreased ADC (blue) when considering the pretreatment mask, and (D)
mostly areas of increased ADCwhen considering the tumor overlap area.
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tissue is being replaced by healthy tissue, rather than the tumor
progressing by becoming more cellular. Furthermore, an increase
in ADC in low-grade tumors is more likely to be associated with
an increase in necrotic regions and, as shown in this study, tumor
response cannot be inferred from these areas.
Change in Tumor Size
Previous work has shown how image registration, particularly due
to an increase in tumor size,may be amajor limitation to the tech-
nique employed in the fDM, andmethods of nonlinear registration
may be beneficial.19 In the cases investigated in this study, there
was a considerable decrease in tumor size. In tumor regions
replaced by healthy tissue, a decrease in ADC was observed in
the areas where there was a reduction in size back to healthy
tissue and an increase in ADC where tumor areas were replaced
by cerebrospinal fluid. In the leftover tumor volume, areas of
decreased ADC were limited, and hence no inference could be
made as regards treatment success or progression. Given the
limited number of patients in this group, we cannot conclude
whether reduction in size is a confounder in the fDM when using
linear registration; however, a reduction in size is alreadyan indica-
tor of treatment success, and the fDM does not appear to give any
further information in the casesweanalyzed. That said, changes in
tumor size need to be treated with caution, and careful visual in-
spection of registered images needs to be carried out in order to
avoid problems of registration due to a change in tumor size.
Study Limitations
Themain limitationof this study is that itwascarriedoutonagroup
of childhood brain tumors with small numbers of similar tumors.
However, different tumor types were specifically selected so that
the fDM could be evaluated in pediatric tumors of differing
grades. Case ascertainment was limited by the rarity of childhood
brain tumors and the fact that patients often arrive at our institu-
tion with pretreatment imaging that did not include comparable
DWI that would allow an fDM to be generated. Surgery took
place immediately in some cases, and hence the fDM could only
be applied to 2 posttreatment images. However, fDM results
were compared with clinical imaging reports at time of follow-up
(second) imaging, rather than final clinical outcome, to minimize
this limitation. Further analyses are warranted on other tumor
types and in larger numbers in order to evaluate more fully the
effects of the confounders described here on the fDM.
Conclusion
In conclusion, our results have shown that, while the fDMmaybe a
useful tool for determining tumor treatment response, careful in-
terpretation needs to be carried out that considers the underlying
biology of both tumor and healthy tissue in order to determine
whether a tumor is responding positively to treatment or not.
Areas of necrosis, tumor grade, and change in tumor size are all
factors that need to be taken into account when carrying out
fDM analyses.
Funding
This work was funded by Cancer Research UK, grant number C7809/
A10342.
Acknowledgments
Thanks to Tina Banks at Great Ormond Street Hospital for Children, London,
and Patrick Hales and Martin King at UCL Institute of Child Health, London,
for their help in this study.
Conflict of interest statement. None declared.
References
1. Fleming AJ, Chi SN. Brain tumors in children. Curr Probl Pediatr Adolesc
Health Care. 2012;42(4):80–103.
2. Jones C, Perryman L, Hargrave D. Paediatric and adult malignant
glioma: close relatives or distant cousins?. Nat Rev Clin Oncol. 2012;
9(7):400–413.
3. Bull JG, Saunders DE, Clark CA. Discrimination of paediatric brain
tumours using apparent diffusion coefficient histograms. Eur Radiol.
2012;22(2):447–457.
Fig. 7. Histological comparisonof low-andhigh-grade tumors. A comparisonof a low-gradeOPG (B),withahistological diagnosisof pilocytic astrocytoma
(WHO grade I) and a high-grade GBM (C) are shown together with a comparative image from normal-appearing white matter (WM) (A). The low-grade
tumor showed some areas with high cellularity (as compared with WM) as well as myxoid areas shown in B. The microcystic changes observed in the
low-grade tumor could explain the increased ADC observed in these tumors when compared with normal-appearing white matter. The high-grade
tumor (C) showed the highest cellularity, which restricts diffusion and explains why these tumors appear dark in ADC images. (All images are
hematoxylin-eosin stained and at the samemagnification [x20].)
Grech-Sollars et al.: Challenges for the fDM in pediatric brain tumors
Neuro-Oncology 455
 at U
CL Library Services on July 24, 2014
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
4. Grech-Sollars M, Saunders DE, Phipps KP, Clayden JD, Clark CA.
Survival analysis for apparent diffusion coefficient measures in
children with embryonal brain tumours. Neuro Oncol. 2012;14(10):
1285–1293.
5. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted
MRI with echo-planar technique in the evaluation of cellularity in
gliomas. J Magn Reson Imaging. 1999;9(1):53–60.
6. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion
map: a noninvasive MRI biomarker for early stratification of
clinical brain tumor response. Proc Natl Acad Sci USA. 2005;
102(15):5524–5529.
7. HamstraDA,Chenevert TL,MoffatBA, etal. Evaluationof the functional
diffusionmapasanearly biomarkerof time-to-progressionandoverall
survival in high-grade glioma. Proc Natl Acad Sci USA. 2005;102(46):
16759–16764.
8. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional
diffusion maps (fDMs) as a biomarker for human glioma cellularity. J
Magn Reson Imaging. 2010;31(3):538–548.
9. Li X, Ashana AO, Moretti VM, Lackman RD. The relation of tumour
necrosis and survival in patients with osteosarcoma. Int Orthop.
2011;35(12):1847–1853.
10. Packer RJ, Boyett JM, Zimmerman RA, et al. Outcome of children with
brain stem gliomas after treatment with 7800 cGy of
hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II
Trial. Cancer. 1994;74(6):1827–1834.
11. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy
and necrosis in cancer treatment. Clin Cancer Res. 2007;13(24):
7271–7279.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
Cell. 2011;144(5):646–674.
13. Hamstra DA, Galba´n CJ, Meyer CR, et al. Functional diffusionmap as an
early imaging biomarker for high-grade glioma: correlation with
conventional radiologic response and overall survival. J Clin Oncol.
2008;26(20):3387–3394.
14. Galba´n CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of
parametric response map-derived MRI biomarkers: identification of
early and distinct glioma response patterns not predicted by
standard radiographic assessment. Clin Cancer Res. 2011;17(14):
4751–4760.
15. Ellingson BM, Cloughesy TF, Zaw T, et al. Functional diffusion maps
(fDMs) evaluated before and after radiochemotherapy predict
progression-free and overall survival in newly diagnosed
glioblastoma. Neuro Oncol. 2012;14(3):333–343.
16. Yasin S, HarknessW, Cross J, Cohen N, Jacques T. Subependymal Giant
Cell Astrocytoma (SEGA) cells respond to rapamycin in vitro.Neuropath
Appl Neuro. 2010;0:41–42.
17. Ghent AW. A Method for Exact Testing of 2X2, 2X3, 3X3, and Other
Contingency Tables, Employing Binomial Coefficients. Am Midl Nat.
1972;88(1):15–27.
18. Cardillo G. MyFisher33: a very compact routine for Fisher’s exact test
on 3×3 matrix. 2007. http://www.mathworks.co.uk/matlabcentral/
fileexchange/15482-myfisher33 (last accessed 15 November 2013).
19. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear
registration of diffusion-weighted images improves clinical sensitivity
of functional diffusion maps in recurrent glioblastoma treated with
bevacizumab. Magn Reson Med. 2012;67(1):237–245.
Grech-Sollars et al.: Challenges for the fDM in pediatric brain tumors
456
 at U
CL Library Services on July 24, 2014
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
